{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:57:46Z","timestamp":1793386666736,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02990-6","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T11:01:55Z","timestamp":1717844515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["An update on the safety of hydroquinone"],"prefix":"10.1007","volume":"316","author":[{"given":"Kavya","family":"Shivaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-1912","authenticated-orcid":false,"given":"Katherine","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1374-1815","authenticated-orcid":false,"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"2990_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1468-3083.2006.01670.x","volume":"20","author":"JJ Nordlund","year":"2006","unstructured":"Nordlund JJ, Grimes PE, Ortonne JP (2006) The safety of hydroquinone. J Eur Acad Dermatol Venereol 20:781\u2013787. https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01670.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2990_CR2","unstructured":"US Food and Drug Administration (2022) FDA works to protect consumers from potentially harmful OTC skin lightening products. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-works-protect-consumers-potentially-harmful-otc-skin-lightening-products. Accessed 31 July 2023"},{"key":"2990_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jaad.2021.12.065","volume":"88","author":"D Ko","year":"2023","unstructured":"Ko D, Wang RF, Ozog D, Lim HW, Mohammad TF (2023) Disorders of hyperpigmentation. Part II. Review of management and treatment options for hyperpigmentation. J Am Acad Dermatol 88:291\u2013320. https:\/\/doi.org\/10.1016\/j.jaad.2021.12.065","journal-title":"J Am Acad Dermatol"},{"key":"2990_CR4","doi-asserted-by":"publisher","first-page":"e48840","DOI":"10.7759\/cureus.48840","volume":"15","author":"IM Fabian","year":"2023","unstructured":"Fabian IM, Sinnathamby ES, Flanagan CJ, Lindberg A, Tynes B, Kelkar RA, Varrassi G, Ahmadzadeh S, Shekoohi S, Kaye AD (2023) Topical hydroquinone for Hyperpigmentation. Narrative Rev Cureus 15:e48840. https:\/\/doi.org\/10.7759\/cureus.48840","journal-title":"Narrative Rev Cureus"},{"key":"2990_CR5","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.3390\/jcm12134341","volume":"12","author":"M Lazar","year":"2023","unstructured":"Lazar M, De La Garza H, Vashi NA (2023) Exogenous ochronosis: characterizing a rare disorder in skin of Color. J Clin Med 12:4341","journal-title":"J Clin Med"},{"key":"2990_CR6","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1097\/ICO.0000000000002027","volume":"38","author":"EJ Hollick","year":"2019","unstructured":"Hollick EJ, Igwe C, Papamichael E, Gore DM, Angunawela RI, Philippidou M, Jones SM (2019) Corneal and scleral problems caused by skin-lightening creams. Cornea 38:1332\u20131335. https:\/\/doi.org\/10.1097\/ICO.0000000000002027","journal-title":"Cornea"},{"key":"2990_CR7","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/exd.13844","volume":"28","author":"S-H Kwon","year":"2019","unstructured":"Kwon S-H, Na J-I, Choi J-Y, Park K-C (2019) Melasma: updates and perspectives. Exp Dermatol 28:704\u2013708. https:\/\/doi.org\/10.1111\/exd.13844","journal-title":"Exp Dermatol"},{"key":"2990_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.det.2010.08.010","volume":"29","author":"B Ladizinski","year":"2011","unstructured":"Ladizinski B, Mistry N, Kundu RV (2011) Widespread use of toxic skin lightening compounds: medical and psychosocial aspects. Dermatol Clin 29:111\u2013123. https:\/\/doi.org\/10.1016\/j.det.2010.08.010","journal-title":"Dermatol Clin"},{"key":"2990_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.annder.2009.12.008","volume":"137","author":"F Ly","year":"2010","unstructured":"Ly F, Kane A, D\u00e9me A, Ngom NF, Niang SO, Bello R, Rethers L, Dangou JM, Dieng MT, Diousse P, Ndiaye B (2010) [First cases of squamous cell carcinoma associated with cosmetic use of bleaching compounds]. Ann Dermatol Venereol 137:128\u2013131. https:\/\/doi.org\/10.1016\/j.annder.2009.12.008","journal-title":"Ann Dermatol Venereol"},{"key":"2990_CR10","doi-asserted-by":"publisher","first-page":"B11","DOI":"10.1016\/j.jid.2022.05.936","volume":"142","author":"B Miles","year":"2022","unstructured":"Miles B, Wilkerson M (2022) LB918 the dark side of hydroquinone for skin lightening: 3-fold increased risk of skin cancer - a cohort study [abstract]. J Invest Dermatology 142:B11","journal-title":"J Invest Dermatology"},{"key":"2990_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2407-14-6","volume":"14","author":"M North","year":"2014","unstructured":"North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD (2014) Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer 14:6. https:\/\/doi.org\/10.1186\/1471-2407-14-6","journal-title":"BMC Cancer"},{"key":"2990_CR12","doi-asserted-by":"publisher","first-page":"542168","DOI":"10.1155\/2013\/542168","volume":"2013","author":"FJ Enguita","year":"2013","unstructured":"Enguita FJ, Leit\u00e3o AL (2013) Hydroquinone: Environmental Pollution, Toxicity, and Microbial answers. Biomed Res Int 2013:542168. https:\/\/doi.org\/10.1155\/2013\/542168","journal-title":"Biomed Res Int"},{"key":"2990_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000454719","volume":"29","author":"B Desmedt","year":"2017","unstructured":"Desmedt B, Ates G, Courselle P, De Beer JO, Rogiers V, Hendrickx B, Deconinck E, De Paepe K (2017) In vitro dermal absorption of Hydroquinone: protocol validation and applicability on illegal skin-whitening cosmetics. Skin Pharmacol Physiol 29:300\u2013308. https:\/\/doi.org\/10.1159\/000454719","journal-title":"Skin Pharmacol Physiol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T16:31:16Z","timestamp":1725899476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["2990"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02990-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TFM has served as an investigator for Estee Lauder, Allergan, Unigen, and Ferndale Laboratories. She has served as a consultant for Beiersdorf and on an advisory board for Ferndale Laboratories. KS and KE declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"TFM has served as an investigator for Estee Lauder, Allergan, Unigen, and Ferndale Laboratories. She has served as a consultant for Beiersdorf and on an advisory board for Ferndale Laboratories. KS and KE declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}